Literature DB >> 12415005

Loss of Rb overrides the requirement for ERK activity for cell proliferation.

Giovanna M D'Abaco1, Steven Hooper, Hugh Paterson, Christopher J Marshall.   

Abstract

The Ras GTPase is a critical transducer of mitogenic signals ultimately leading to inactivation of the retinoblastoma (Rb) protein, but the molecular basis underlying Ras-dependent control of cell cycle kinetics remains to a great extent unknown. In an effort to further elucidate the role of Ras activation in cell cycle control, we have studied the role of the downstream Mek-ERK pathway in facilitating exit from the quiescent G0 state and passage through the G1/S transition. We have adopted a genetic approach in combination with U0126, an inhibitor of Mek activation to study the role of Mek in cell cycle progression. Here we report that whereas wild-type (Wt) mouse embryo fibroblasts (MEFs) depend on ERK activation to enter the cell cycle, Rb-deficient (Rb(-/-)) MEFs have a reduced requirement for ERK signalling. Indeed in the presence of U0126 we found that Rb-null MEFs can exit G0, make the G1/S transition and proliferate. Analysis of Rb-deficient tumour cell lines also revealed a reduced requirement for ERK signalling in asynchronous growth. We discuss the molecular mechanism that may underlie this escape from MAP kinase signalling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415005     DOI: 10.1242/jcs.00161

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  18 in total

1.  ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression.

Authors:  Lionel Le Gallic; Laura Virgilio; Philip Cohen; Benoit Biteau; George Mavrothalassitis
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 2.  Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

Authors:  James DeGregori
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

3.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

4.  Somatic excision demonstrates that c-Jun induces cellular migration and invasion through induction of stem cell factor.

Authors:  Sanjay Katiyar; Xuanmao Jiao; Erwin Wagner; Michael P Lisanti; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

5.  Targeting the RB-pathway in cancer therapy.

Authors:  Erik S Knudsen; Jean Y J Wang
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 6.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

7.  Glycine- and proline-rich glycoprotein regulates the balance between cell proliferation and apoptosis for ACF formation in 1,2-dimethylhydrazine-treated A/J mice.

Authors:  Sei-Jung Lee; Kye-Taek Lim
Journal:  Mol Cell Biochem       Date:  2009-01-31       Impact factor: 3.396

8.  ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-independent disruption of retinoblastoma-lamin A complexes.

Authors:  Javier Rodríguez; Fernando Calvo; José M González; Berta Casar; Vicente Andrés; Piero Crespo
Journal:  J Cell Biol       Date:  2010-11-29       Impact factor: 10.539

9.  Mutation of the Rb1 pathway leads to overexpression of mTor, constitutive phosphorylation of Akt on serine 473, resistance to anoikis, and a block in c-Raf activation.

Authors:  Shahenda El-Naggar; Yongqing Liu; Douglas C Dean
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

Review 10.  Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer.

Authors:  Rebecca K Davis; Srikumar Chellappan
Journal:  Drug News Perspect       Date:  2008 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.